MRManuel Rodríguez

Manuel Rodríguez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Manuel Rodríguez has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: insights from a multicenter European cohort.

    by Sabela Lens, Habiba Kamal, Arno Furquim D’ALmeida, Sara Battistella, Segolene Brichler, Margarita Papatheodoridi, Adriana Palom, Marta Casado, Stefan Bourgeois, Moisés Diago, et al.


  • Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN study

    by Ángela Puente, Fanny Turón, Javier Martínez, Jose Ignacio Fortea, Manuel Hernández Guerra, Edilmar Alvarado, Mónica Pons, Marta Magaz, Elba Llop, Carmen Alvarez-Navascués, et al.


  • Open Access

    Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes

    by Marta Fortuny, Marta García-Calonge, Óscar Arrabal, Marco Sanduzzi-Zamparelli, Andrés Castaño-García, Enric Cascos, Alicia Mesa, Ana María Piedra-Cerezal, Neus Llarch, Gemma Iserte, et al.


  • Open Access

    Evolving epidemiology of HCC in Spain

    by Margarita Sala, Sonia Pascual, Maria Rosa Rota Roca, Ana María Matilla, Marta Campos, Manuel Delgado, María Teresa Ferrer, José Luís Montero, Jesús Manuel González-Santiago, Antonio Guerrero, et al.


  • Porto-sinusoidal vascular liver disorder with portal hypertension: Natural history and long-term outcome

    by Marta Magaz, Heloïse Giudicelli-Lett, Juan G. Abraldes, Oana Nicoară-Farcău, Fanny Turon, Neil Rajoriya, Ashish Goel, Karlien Raymenants, Sophie Hillaire, Luis Téllez, et al.


  • Open Access

    Real‐life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

    by Juan Carlos Ruiz‐Cobo, Jordi Llaneras, Xavier Forns, Adolfo Gallego Moya, Isabel Conde Amiel, Ana Arencibia, Moises Diago, Javier García‐Samaniego, Jose Castellote, Susana Llerena, et al.

    Summary: Background: Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is the recommended rescue therapy for patients with chronic hepatitis C infection who fail direct‐acting antivirals (DAAs). Data are limited on the effectiveness of this treatment after the current first‐line therapies. Our aim was to analyse the effectiveness and safety of SOF/VEL/VOX among patients failing sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB). Methods: Retrospective multicentre study (26 Spanish hospitals), including chronic hepatitis C patients unsuccessfully treated with SOF/VEL or GLE/PIB, and retreated with SOF/VEL/VOX ± ribavirin for 12 weeks between December 2017 and December 2022. Results: In total, 142 patients included: 100 (70.4%) had failed SOF/VEL and 42 (29.6%) GLE/PIB. Patients were mainly men (84.5%), White (93.9%), with hepatitis C virus genotype (GT) 3 (49.6%) and 47.2% had liver cirrhosis. Sustained virological response (SVR) was evaluated in 132 patients who completed SOF/VEL/VOX and were followed 12 weeks after end of treatment; 117 (88.6%) achieved SVR. There were no significant differences in SVR rates according to initial DAA treatment (SOF/VEL 87.9% vs. GLE/PIB 90.2%, p = 0.8), cirrhosis (no cirrhosis 90% vs. cirrhosis 87.1%, p = 0.6) or GT3 infection (non‐GT3 91.9% vs. GT3 85.5%, p = 0.3). However, when considering the concurrent presence of SOF/VEL treatment, cirrhosis and GT3 infection, SVR rates dropped to 82.8%. Ribavirin was added in 8 (6%) patients, all achieved SVR. Conclusion: SOF/VEL/VOX is an effective rescue therapy for failures to SOF/VEL or GLE/PIB, with an SVR of 88.6%. Factors previously linked to lower SVR rates, such as GT3 infection, cirrhosis and first‐line therapy with SOF/VEL were not associated with lower SVRs.


  • Predictive models for hepatocellular carcinoma development after sustained virological response in advanced hepatitis C

    by Miguel Fraile-López, Carmen Alvarez-Navascués, María Luisa González-Diéguez, Valle Cadahía, Valentina Chiminazzo, Andrés Castaño, María Varela, Manuel Rodríguez

  • Prevalencia y patrón de consumo de alcohol en pacientes con carcinoma hepatocelular

    by Daniel Muiño-Domínguez, Alejandro Mínguez-Sabater, Eduardo Junquera-Alonso, Ana María Piedra-Cerezal, Manuel Rodríguez, María Varela

  • Open Access

    Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B

    by Beatriz Mateos-Muñoz, María Buti, Inmaculada Fernández Vázquez, Marta Hernández Conde, Vanesa Bernal-Monterde, Fernando Díaz-Fontenla, Rosa María Morillas, Luisa García-Buey, Ester Badía, Mireia Miquel, et al.

    Background and Aims HIV-positive patients on tenofovir hydroxyl fumarate (TDF)/emtricitabine have a lower risk of COVID-19 and hospitalization than those given other treatments. Our aim was to analyze the severity of COVID-19 in patients with chronic hepatitis B (CHB) on TDF or entecavir (ETV). Methods Spanish hospital databases (n = 28) including information regarding adult CHB patients on TDF or ETV for the period February 1st to November 30th 2020 were searched for COVID-19, defined as a positive SARS-CoV-2 polymerase chain reaction, and for severe COVID-19. Results Of 4736 patients, 117 had COVID-19 (2.5%), 67 on TDF and 50 on ETV. Compared to patients on TDF, those on ETV showed (p < 0.05) greater rates of obesity, diabetes, ischemic cardiopathy, and hypertension. COVID-19 incidence was similar in both groups (2.3 vs. 2.6%). Compared to TDF, patients on ETV more often (p < 0.01) had severe COVID-19 (36 vs. 6%), required intensive care unit (ICU) (10% vs. 0) or ventilatory support (20 vs. 3%), were hospitalized for longer (10.8 ± 19 vs. 3.1 ± 7 days) or died (10 vs. 1.5%, p = 0.08). In an IPTW propensity score analysis adjusted for age, sex, obesity, comorbidities, and fibrosis stage, TDF was associated with a sixfold reduction in severe COVID-19 risk (adjusted-IPTW-OR 0.17, 95%CI 0.04–0.67, p = 0.01). Conclusion Compared to ETV, TDF seems to play a protective role in CHB patients with SARS-CoV-2 whereby the risk of severe COVID-19 is lowered.


  • Open Access

    THE ACADEMIC IMPACT OF THE SYMPOSIUM ON ENDOSCOPY AND MINIMALLY INVASIVE SPINE SURGERY OF THE MEXICAN ASSOCIATION OF SPINE SURGEONS – AMCICO

    by Alfonso Garcia, Eulalio Elizalde Martínez, Iliana Margarita Gómez Silva, Javier Quillo-Olvera, Cesar A. Alcántara Canseco, Manuel Rodriguez Garcia, Sergio Soriano Solis, Stefan Hellinger, Paul Houle, Raymond Gardocki, et al.

    Introduction: The interest in spinal endoscopy is rising, particularly among younger spine surgeons. Formalized postgraduate training programs for endoscopic spinal surgery techniques are lacking behind. Methods: The authors performed a retrospective survey study amongst participants of the 2022 AMCICO endoscopic surgery symposium. Descriptive and correlative statistics were done on the surgeon’s responses recorded in multiple-choice questions. In addition, surgeons were asked about their clinical experience and preferences with spinal endoscopy, training background, the types of lumbar endoscopic decompression they perform by approach, and future training requirements. SPSS (version 27) statistical software package was used for data analysis. Descriptive statistic measures were used to count responses and calculate the mean, range, standard deviation, and percentages. In addition, chi-square statistics were used to determine the strength of the association between factors. Results: The online survey was accessed by 321 surgeons, of which 92 completed it (53.4%). Demographic data showed the majority of responding surgeons being orthopedic surgeons (73.6%) and under the age of 50 (69.2%), with over half (51.1%) having less than three months of formalized training in endoscopic spinal surgery techniques. Most surgeons practiced uni-portal (58.9%) versus bi-portal (3.4%) spinal endoscopy. The transforaminal approach (65.5%) was preferred over the interlaminar method (34.4%). The bi-portal technique was indicated almost exclusively for the lumbar spine (94.8%). For endoscopically assisted spinal fusions, a uni-portal approach was preferred by 72% of surgeons over a bi-portal procedure (24.5%). 84.1% of respondents were interested in navigation, of which 30.7% preferred optical over electromagnetic technology (18.2%). Robotics was of interest to 51.1% of survey participants. Respondents’ bias was estimated with course attendance assessments, with 37% of surgeons having attended all three days, 27.2% two days, and 16.3% one day. One-fifth of responding spine surgeons did not participate in any curriculum activities but completed the survey. The academic impact of the AMCICO endoscopy symposium was high, with 68.1% of respondents indicating interest in continued training and 61.1% of trainees ready to apply their newly acquired knowledge base to clinical practice. Conclusion: The interest in spinal endoscopy surgery techniques and protocols is high among AMCICO members. Many surgeons are interested in learning advanced endoscopic surgical techniques to integrate the technology into their surgical procedure portfolio to address common painful conditions of the degenerative spine beyond herniated discs and foraminal stenosis. The authors concluded that its academic impact was high based on the responses given by the participating surgeons. Level of evidence III; Retrospective study.